Bayer and Kumquat Biosciences have entered into an exclusive global license and collaboration agreement to develop and commercialise Kumquat’s KRAS G12D inhibitor.   Under the agreement, Kumquat is responsible for the initiation and completion of the Phase Ia study, while Bayer will complete development and commercial activities.  Kumquat received US Food and Drug Administration (FDA) clearance […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!